New Drug Applications Archive - April 2014
Get news by email or subscribe to our news feeds.
April 1, 2014
April 2, 2014
April 4, 2014
April 7, 2014
- Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C
- Gilead Announces FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination
- MannKind Updates Status of New Drug Application for Afrezza
April 11, 2014
April 14, 2014
- Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat
- Alimera Sciences Announces New PDUFA Date For Iluvien
- Boehringer Ingelheim and Eli Lilly Announce NDA Filing for Empagliflozin and Linagliptin Combination
April 21, 2014
- Sarepta Therapeutics Announces Plans to Submit NDA to FDA for Eteplirsen for Duchenne Muscular Dystrophy
- Gilead Sciences’ New Drug Application for Cobicistat for HIV Therapy Accepted by U.S. FDA
- Gilead Sciences’ New Drug Application for Elvitegravir for HIV Therapy Accepted by U.S. FDA
April 22, 2014
- AbbVie Submits NDA to FDA for Oral, Interferon-Free Therapy for the Treatment of Hepatitis C
- QRxPharma Issues Statement On Moxduo Advisory Committee Meeting
